Back

Amyloid-β precursor protein promotes tumor growth by establishing an immune-exclusive tumor microenvironment

Yin, T.; Wang, G.; Ma, Z.; Wang, L.; Chen, R.; Xiang, K.; Tan, L.; Wang, Y.; Chong, M.; Liang, Y.; Pan, C. C.; Alexander, P. B.; Lim, B. J. W.; Wang, E.; Liu, B.; Yan, C.; Li, Q.-J.; Wang, X.-F.

2025-02-14 cancer biology
10.1101/2025.02.10.637339 bioRxiv
Show abstract

During initiation and progression, cancerous tissue hijacks a series of elaborate tissue homeostatic mechanisms to avoid immune surveillance, including neuro-immune interactions. Here, we show that amyloid-{beta} precursor protein (APP) and its {beta}-cleavage product amyloid-{beta}1-42 (A{beta}1-42), well-known in the pathogenesis of Alzheimers disease (AD), are expressed in multiple cancer tissues. However, the oncogenic activity of APP is due to its E1 domain, instead of A{beta}1-42. Mechanistically, APP restricts immune cells influx into tumor microenvironment (TME) and impairs CD8+ T cell and NK cell-based immunity, by dampening type I interferon (IFN) response in TME. We also provide proof-of-concept that vaccination targeting APP is effective for cancer prevention. Our current study reveals a previously unrecognized role of APP in cancer immune surveillance, and provides a new strategy for cancer prevention and treatment by targeting APP.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.